Odyssey Group International, Inc. (OTC:ODYY)

We are a specialty medical company focused on the development and acquisition of life saving medical products and health related technologies.

  • Publicly traded on OTC ticker ODYY

  • CardioMap Heart Monitoring and Screening Device (in development)

  • Save-A-Life Choking Rescue device (in development)

  • Neurosteroid drug for treating brain related illness

Our mission is to acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that are under-valued and can be enhanced by our company internally or through strategic partnerships.
Ultimately our goal is to deliver superior products with enhanced clinical utility resulting in financial results, which yield a high rate of return for our shareholders and partners. Odyssey’s senior management team has significant experience with the capabilities to further refine acquired technologies, build commercial systems and/or create strategic partnerships.

Odyssey Board of Directors

Michael Redmond –
President and CEO

Mr. Redmond has over 30 years commercial experience in medical device companies. Mr. Redmond held various sales and marketing positions at Abbott Laboratories, a multi-billion dollar healthcare company. Mr. Redmond then went on to help start KMC Systems Inc., now a leading private label developer and manufacturer of medical devices. Mr. Redmond was in charge of Sales and Marketing and grew the company from start-up to over $50M in revenue. KMC was sold to Elbit systems in 1996. Mr. Redmond then joined Bioject Inc as its VP of Sales and Marketing. Bioject was a medical device company specializing in unique drug delivery technologies.

Mr. Redmond helped raise over $15M in capital, entered several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10M to over $400M. Mr. Redmond was VP of Business Development for DxTech, Inc a start up company developing a unique point of care diagnostic testing platform. DxTech was sold in 2009. Mr. Redmond was recently CEO of Parallax Health Sciences, Inc. where he acquired two business and three different patented technologies.

Jeff Conroy –

Jeff Conroy is an operating and business development executive with over 30 years in the life science industry across therapeutics and medical devices. Jeff is the Chairman & CEO of Embody, a DARPA- funded medical device company developing regenerative implants for tendon and ligament repair. Previously, Jeff was the President of TissueNet, an AATB-accredited tissue bank. He is also the Managing Director of Windward Investments structuring licensing partnerships for life science companies. Since 2012, Jeff has served as the Head of Corporate Development for Especificos Stendhal S.A. de C.V., a Latin American specialty pharmaceutical company. Jeff is an Independent Director of Cingulate Therapeutics, a CNS company developing ADHD therapeutics. Jeff holds a B.S. in Business Administration from Providence College.

Jerry Casey –

Jerry Casey has been a leader in the life science industry for over 30 years. Enjoying a long tenure as a senior executive at Genzyme Corporation, Mr. Casey was the driver behind Genzyme’s commercial success in the diagnostics arena, building a $175M business which Genzyme sold to Japan-based Sekisui Chemical in 2011. Mr. Casey became the President and Chief Operating Officer of the new entity, Sekisui Diagnostics, LLC, until the end of 2014. Since leaving the company, Mr. Casey has been actively involved in several life sciences ventures, both as an advisor and an investor, while serving on multiple Boards. While President and COO, Mr. Casey established the strategic direction for the company; led the global organization, including the commercial, operations, research and development, finance, HR, and legal functions; and achieved the annual and long-term financial objectives of the business.

Jacob ‘Jake’ W. VanLandingham –

Jake is the Founder and President of Prevacus, Inc. Jake has a B.S. in Physical Therapy and spent 3- years working with neurologically-impaired children with brain injuries in and around the time of birth. His Ph.D is in Neuroscience from Florida State University with a molecular biology focus on disease. His Post-doctoral work was in translational research and neurobehavioral aspects of diseases at Emory University. At Emory he also oversaw the clinical biomarker study for the ProTECT clinical trial using progesterone for acute treatment of severe to moderate TBI as the Assistant Director of the Brain Research Laboratory the largest laboratory in the Emergency Medicine Department. Jake has an excellent teaching record and has won multiple awards with both graduate and undergraduate students. He was a Year One Director of the Florida State University Medical

School for 8 years before devoting all of his’ time to Prevacus, Inc. starting in 2015.

John Gandolfo –

On October 23, 2019, John Gandolfo, joined the Board of Odyssey as an independent director and has been elected chair of the audit committee.  Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas, companies such as .  Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career.  Mr. Gandolfo is currently Chief Financial Officer of Eyenovio, Inc., a late-stage ophthalmic biopharmaceutical company.  Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. from July 2010 through September 2017. He served as the Chief Financial Officer for Progenitor Cell Therapy LLC from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc. He was also the Chief Financial Officer of Capital Access Network, Inc, from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc.  From 1987 through 1994, he was Chief Financial Officer of Medical Resources; Inc. Mr. Gandolfo received his B.A. in business administration from Rutgers University.

Odyssey International, Inc. (OTC:ODYY)

  • Loading stock data...


Interested in participating in Odyssey via the stock market?


Interested in speaking with a member of our team?